Research Article

Prognosis in IDH-Mutant and IDH-wild type glioblastoma

Volume: 43 Number: 3 September 30, 2021
Cumhuriyet Medical Journal Cover
Cumhuriyet Medical Journal
PDF Download
EN

Prognosis in IDH-Mutant and IDH-wild type glioblastoma

Abstract

Glioblastoma (GBM) is the most common brain tumor in adults with a poor prognosis and predominantly astrocytic differentiation. GBM is classified according to the isocitrate dehydrogenase (IDH) mutation according to the World Health Organization (WHO) Brain Tumors 2016 classification. IDH-1 gene mutations are evaluated immunohistochemically (IHC) and molecular methods in current pathology laboratory practice.
The aim of this study was to determine the overall survival in GBM cases according to IDH-1 mutation status and Ki-67 proliferation index.
Total of 53 patients diagnosed as GBM between 2007-2020 in Sivas Cumhuriyet University Faculty of Medicine, Department of Pathology were evaluated. Disease-free median survival of 7 (13%) GBM patients with IDH mutation was 2 months (2-year survival 14%), disease-free median survival 9 months (2-year survival 24 %) in GBM IDH-wild type cases. In cases with a higher Ki-67 proliferation index, the median disease-free survival were shorter.
In conclusion statistically significant results could not be obtained between disease-free survival in GBM IDH-mutant type and GBM IDH-wild type. However, the mean Ki-67 proliferation index of GBM IDH-wild type cases was found to be much higher than GBM IDH-mutant cases. High Ki-67 proliferation index was found to be associated with a significantly shorter survival.

Keywords

Supporting Institution

Sivas Cumhuriyet Üniversitesi Bilimsel Araştırma Projeleri (CÜBAP)

Project Number

T-902

References

  1. 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds). WHO Classification of Tumours of the Central Nervous System. 4th ed, IARC, Lyon 2016. WHO
  2. 2. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol 2018; 20 Suppl
  3. 3. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005; 293: 557.
  4. 4. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Eng l J Med 2009; 360: 765. 5. Gokden M. If it is not Glioblastoma then What is it? A Differential Diagnostic Review. Adv Anat Pathol. 2017 Nov; 24 (6): 379-391. doi: 10.1097/PAP.0000000000000170.
  5. 6. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Basedon 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 2015; 372: 2499.
  6. 7. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencingas a basis foran "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma an dglioblastoma. ActaNeuropathol 2015; 129: 133.
  7. 8. Gramatzki D, Dehler S, Rushing EJ, et all. Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to2009. Cancer. 2016 Jul 15; 122 (14): 2206-2215. doi: 10.1002/cncr.30023. Epub2016 Apr18.
  8. 9. Wirsching HG, Galanis E,Weeler M. Glioblastoma. Handb Clin Neurol 2016; 134: 381-397. doi: 10.1016/B978-0-12-802997-8.00023-2

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Publication Date

September 30, 2021

Submission Date

June 1, 2021

Acceptance Date

August 16, 2021

Published in Issue

Year 2021 Volume: 43 Number: 3

DOI

https://doi.org/10.7197/cmj.945850

IZ

https://izlik.org/JA72YU69BZ

Cite

RIS / Bibtex
APA
Kılıç, E., Yeldir, N., Özüm, Ü., Yücel, B., Yılmaz, M., Özer, H., & Eğilmez, R. (2021). Prognosis in IDH-Mutant and IDH-wild type glioblastoma. Cumhuriyet Medical Journal, 43(3), 249-253. https://doi.org/10.7197/cmj.945850
AMA
1.Kılıç E, Yeldir N, Özüm Ü, et al. Prognosis in IDH-Mutant and IDH-wild type glioblastoma. CMJ. 2021;43(3):249-253. doi:10.7197/cmj.945850
Chicago
Kılıç, Eren, Neşe Yeldir, Ünal Özüm, et al. 2021. “Prognosis in IDH-Mutant and IDH-Wild Type Glioblastoma”. Cumhuriyet Medical Journal 43 (3): 249-53. https://doi.org/10.7197/cmj.945850.
EndNote
Kılıç E, Yeldir N, Özüm Ü, Yücel B, Yılmaz M, Özer H, Eğilmez R (September 1, 2021) Prognosis in IDH-Mutant and IDH-wild type glioblastoma. Cumhuriyet Medical Journal 43 3 249–253.
IEEE
[1]E. Kılıç et al., “Prognosis in IDH-Mutant and IDH-wild type glioblastoma”, CMJ, vol. 43, no. 3, pp. 249–253, Sept. 2021, doi: 10.7197/cmj.945850.
ISNAD
Kılıç, Eren - Yeldir, Neşe - Özüm, Ünal - Yücel, Birsen - Yılmaz, Mukaddes - Özer, Hatice - Eğilmez, Reyhan. “Prognosis in IDH-Mutant and IDH-Wild Type Glioblastoma”. Cumhuriyet Medical Journal 43/3 (September 1, 2021): 249-253. https://doi.org/10.7197/cmj.945850.
JAMA
1.Kılıç E, Yeldir N, Özüm Ü, Yücel B, Yılmaz M, Özer H, Eğilmez R. Prognosis in IDH-Mutant and IDH-wild type glioblastoma. CMJ. 2021;43:249–253.
MLA
Kılıç, Eren, et al. “Prognosis in IDH-Mutant and IDH-Wild Type Glioblastoma”. Cumhuriyet Medical Journal, vol. 43, no. 3, Sept. 2021, pp. 249-53, doi:10.7197/cmj.945850.
Vancouver
1.Eren Kılıç, Neşe Yeldir, Ünal Özüm, Birsen Yücel, Mukaddes Yılmaz, Hatice Özer, Reyhan Eğilmez. Prognosis in IDH-Mutant and IDH-wild type glioblastoma. CMJ. 2021 Sep. 1;43(3):249-53. doi:10.7197/cmj.945850